CL2014002847A1 - Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras. - Google Patents
Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras.Info
- Publication number
- CL2014002847A1 CL2014002847A1 CL2014002847A CL2014002847A CL2014002847A1 CL 2014002847 A1 CL2014002847 A1 CL 2014002847A1 CL 2014002847 A CL2014002847 A CL 2014002847A CL 2014002847 A CL2014002847 A CL 2014002847A CL 2014002847 A1 CL2014002847 A1 CL 2014002847A1
- Authority
- CL
- Chile
- Prior art keywords
- schizophrenia
- anxiety
- parkinson
- prophylaxis
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12169954 | 2012-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002847A1 true CL2014002847A1 (es) | 2015-01-30 |
Family
ID=48534382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002847A CL2014002847A1 (es) | 2012-05-30 | 2014-10-22 | Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9394311B2 (es) |
| EP (1) | EP2855455B1 (es) |
| JP (1) | JP5992096B2 (es) |
| KR (1) | KR101666293B1 (es) |
| CN (1) | CN104364249B (es) |
| AR (1) | AR091185A1 (es) |
| AU (1) | AU2013269800A1 (es) |
| BR (1) | BR112014026828A2 (es) |
| CA (1) | CA2868240A1 (es) |
| CL (1) | CL2014002847A1 (es) |
| CO (1) | CO7091174A2 (es) |
| CR (1) | CR20140481A (es) |
| EA (1) | EA201492069A1 (es) |
| IL (1) | IL235829A0 (es) |
| MX (1) | MX2014014468A (es) |
| PE (1) | PE20142366A1 (es) |
| PH (1) | PH12014502294A1 (es) |
| SG (1) | SG11201406890YA (es) |
| TW (1) | TW201402564A (es) |
| WO (1) | WO2013178572A1 (es) |
| ZA (1) | ZA201407695B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015005375A (es) * | 2012-11-07 | 2015-07-21 | Hoffmann La Roche | Compuestos de triazolo. |
| CN110139862B (zh) | 2016-11-03 | 2024-01-16 | 百时美施贵宝公司 | 可用作romk通道抑制剂的经取代的二环杂环衍生物 |
| CN111875583B (zh) * | 2017-10-17 | 2021-06-15 | 中国科学院上海药物研究所 | 三氮唑衍生物及其制备方法和用途 |
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| WO2020094591A1 (en) | 2018-11-06 | 2020-05-14 | H. Lundbeck A/S | Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia |
| WO2020094592A1 (en) | 2018-11-06 | 2020-05-14 | H. Lundbeck A/S | Compounds for treating negative symptoms and cognitive impairments |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| JP7697933B2 (ja) * | 2019-09-25 | 2025-06-24 | オンコアレンディ セラピューティクス エス.エー. | 5-(4-((2s,5s)-5-(4-クロロベンジル)-2-メチルモルホリノ)ピペリジン-1-イル)-1h-1,2,4-トリアゾール-3-アミンの製造プロセス |
| CN113929634A (zh) * | 2021-11-22 | 2022-01-14 | 山西永津集团有限公司 | 一种2,3-二溴喹喔啉的合成方法 |
| EP4739673A1 (en) | 2023-07-06 | 2026-05-13 | Basf Se | Triazole compounds for the control of invertebrate pests |
| EP4488270A1 (en) | 2023-07-06 | 2025-01-08 | Basf Se | Triazole compounds for the control of invertebrate pests |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2744116A (en) * | 1953-12-04 | 1956-05-01 | Purdue Research Foundation | Bis-(aminotriazolyl-)-hydrocarbons |
| TWI274750B (en) * | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
| US6887870B1 (en) * | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| EP1885713A1 (en) * | 2005-05-18 | 2008-02-13 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| US8143264B2 (en) * | 2005-08-10 | 2012-03-27 | Glaxosmithkline Llc | Xanthine derivatives as selective HM74A agonists |
| WO2008103357A1 (en) * | 2007-02-21 | 2008-08-28 | E. I. Du Pont De Nemours And Company | Fungicidal tricyclic 1,2,4-triazoles |
| US20090156594A1 (en) * | 2007-05-21 | 2009-06-18 | Sgx Pharmaceuticals, Inc. | Heterocyclic kinase modulators |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
| TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
| WO2011150156A2 (en) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| BR112013003097B1 (pt) * | 2010-08-12 | 2021-03-16 | Boehringer Ingelheim International Gmbh | 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica |
| US20130225583A1 (en) * | 2010-10-21 | 2013-08-29 | Gerald W. Shipps, Jr. | Substituted amino-triazolyl pde10 inhibitors |
-
2013
- 2013-05-27 WO PCT/EP2013/060838 patent/WO2013178572A1/en not_active Ceased
- 2013-05-27 EP EP13725360.5A patent/EP2855455B1/en not_active Not-in-force
- 2013-05-27 BR BR112014026828A patent/BR112014026828A2/pt not_active Application Discontinuation
- 2013-05-27 JP JP2015514445A patent/JP5992096B2/ja not_active Expired - Fee Related
- 2013-05-27 AU AU2013269800A patent/AU2013269800A1/en not_active Abandoned
- 2013-05-27 KR KR1020147036637A patent/KR101666293B1/ko not_active Expired - Fee Related
- 2013-05-27 CN CN201380027925.9A patent/CN104364249B/zh not_active Expired - Fee Related
- 2013-05-27 PE PE2014001616A patent/PE20142366A1/es not_active Application Discontinuation
- 2013-05-27 EA EA201492069A patent/EA201492069A1/ru unknown
- 2013-05-27 CA CA2868240A patent/CA2868240A1/en not_active Abandoned
- 2013-05-27 MX MX2014014468A patent/MX2014014468A/es unknown
- 2013-05-27 SG SG11201406890YA patent/SG11201406890YA/en unknown
- 2013-05-28 TW TW102118823A patent/TW201402564A/zh unknown
- 2013-05-29 AR ARP130101863 patent/AR091185A1/es unknown
-
2014
- 2014-09-26 CO CO14213791A patent/CO7091174A2/es unknown
- 2014-10-10 PH PH12014502294A patent/PH12014502294A1/en unknown
- 2014-10-16 CR CR20140481A patent/CR20140481A/es unknown
- 2014-10-22 ZA ZA2014/07695A patent/ZA201407695B/en unknown
- 2014-10-22 CL CL2014002847A patent/CL2014002847A1/es unknown
- 2014-11-20 IL IL235829A patent/IL235829A0/en unknown
- 2014-11-25 US US14/552,837 patent/US9394311B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2855455B1 (en) | 2017-11-08 |
| CO7091174A2 (es) | 2014-10-21 |
| WO2013178572A1 (en) | 2013-12-05 |
| CN104364249B (zh) | 2018-04-17 |
| US9394311B2 (en) | 2016-07-19 |
| SG11201406890YA (en) | 2014-11-27 |
| US20150148332A1 (en) | 2015-05-28 |
| PH12014502294A1 (en) | 2014-12-15 |
| AU2013269800A1 (en) | 2014-10-09 |
| TW201402564A (zh) | 2014-01-16 |
| PE20142366A1 (es) | 2015-01-10 |
| KR20150027143A (ko) | 2015-03-11 |
| BR112014026828A2 (pt) | 2017-06-27 |
| ZA201407695B (en) | 2016-08-31 |
| EP2855455A1 (en) | 2015-04-08 |
| JP5992096B2 (ja) | 2016-09-14 |
| CN104364249A (zh) | 2015-02-18 |
| CA2868240A1 (en) | 2013-12-05 |
| KR101666293B1 (ko) | 2016-10-13 |
| EA201492069A1 (ru) | 2015-03-31 |
| AR091185A1 (es) | 2015-01-14 |
| IL235829A0 (en) | 2015-02-01 |
| CR20140481A (es) | 2014-11-17 |
| MX2014014468A (es) | 2015-02-12 |
| JP2015518018A (ja) | 2015-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
| BR112014028395A2 (pt) | derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer | |
| CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
| HUE064667T2 (hu) | Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra | |
| CR20140370A (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| CR11019A (es) | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas | |
| BR112014013843A2 (pt) | uso de dispositivos para o tratamento de doenças neurológicas | |
| CL2016001895A1 (es) | Compuestos | |
| CO6930363A2 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| BRPI0716844A2 (pt) | Inidores de quinase úteis para o tratamento de doenças proliferativas | |
| HUE053113T2 (hu) | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| MX382599B (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina. | |
| CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| BRPI0819241A2 (pt) | Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas | |
| HUE056006T2 (hu) | Kombináció Parkinson-kór kezelésére | |
| CL2013002341A1 (es) | Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros | |
| PT2838539T (pt) | Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos. | |
| PL2935274T3 (pl) | Pochodne 3-okso-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pirymidyny do leczenia chorób układu oddechowego | |
| BR112014010183A2 (pt) | composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase | |
| CL2014000641A1 (es) | Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras. | |
| CL2015000559A1 (es) | Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras. | |
| PT2056804E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares |